Blog & Resources Camargo Blog September 21st, 2007

PDUFA 2007—New Submisson Fees for 505(b)(2) Applications

Congress just passed the Food and Drug Administration Amendments Act of 2007. Most of us in 505(b)(2) drug development will think of it as the PDUFA 2007 (Prescription Drug User Fee Amendments of 2007). This amendment covers the period from 2008-2012 (plus, to circumvent the rush experienced with this re-authorization, provisions for an extra 3 months into FY 2013).

Congress authorized charging $50 million more than requested by FDA or pharma. Clearly, this will result in higher fees by pharma. Once signed by the President, FDA will compute the actual charge per application. Stay tuned…

Get Our Expertise Working for You

To learn how you can benefit from our regulatory and strategic development expertise, view our solutions or contact us.

Camargo Pharmaceutical Services provides comprehensive drug development solutions, specializing in customized programs including the 505(b)(2) pathway.

9825 Kenwood Road
Suite 203
Cincinnati OH, 45242
Durham Office
800 Taylor Street
Suite 101
Durham NC, 27701
Montreal Office
507 Place d'Armes
Suite 1101
Montreal, QC H2Y 2W8, Canada
Phone 513.561.3329
Toll Free 888.451.5708
Subscribe for our Latest Insights